BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11734942)

  • 1. Bilateral breast involvement in Sézary syndrome.
    Balci P; Undar B; Yilmaz E; Seçil M; Ozsan H; Canda T
    Eur Radiol; 2001; 11(12):2468-71. PubMed ID: 11734942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic imaging in the initial staging of mycosis fungoides and Sézary syndrome.
    Kulin PA; Marglin SI; Shuman WP; Chew DE; Olerud JE
    Arch Dermatol; 1990 Jul; 126(7):914-8. PubMed ID: 2360839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma.
    Kamstrup MR; Gniadecki R; Friberg L
    Arch Dermatol; 2012 Dec; 148(12):1420-2. PubMed ID: 23247490
    [No Abstract]   [Full Text] [Related]  

  • 4. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
    Sentis HJ; Willemze R; Scheffer E
    J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency and significance of radiographic findings in the staging workup of patients with mycosis fungoides and Sezary syndrome.
    Eckburg A; Mott S; Dittmer M; Zafar F; Link B; Liu V
    Int J Dermatol; 2023 May; 62(5):e315-e318. PubMed ID: 35506495
    [No Abstract]   [Full Text] [Related]  

  • 6. Sézary syndrome in an 11-year-old girl.
    Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
    J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK; Mullins FM; Kim YH; Kong CS
    Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mycosis fungoides and Sézary syndrome : a systematic review].
    André F; Guenova E; Blanchard G
    Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
    So CC; Wong KF; Siu LL; Kwong YL
    Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides/Sézary syndrome: report of an unusual case.
    Mehta A; Dhungel BM; Khan MF
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
    Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
    Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
    Pulitzer MP; Horna P; Almeida J
    Cytometry B Clin Cytom; 2021 Mar; 100(2):132-138. PubMed ID: 32516521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is bone marrow biopsy necessary in patients with mycosis fungoides and Sézary syndrome? A histological and molecular study at diagnosis and during follow-up.
    Beylot-Barry M; Parrens M; Delaunay M; Thiebault R; Vergier B; DeMascarel A; Dubus P; Beylot C; Merlio JP
    Br J Dermatol; 2005 Jun; 152(6):1378-9. PubMed ID: 15949023
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
    Yamashita T; Abbade LP; Marques ME; Marques SA
    An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.